The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...

At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone ...

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...

“ATX-01 is a very unique molecule – it was discovered and developed entirely in-house by ARTHEx scientists through years of engineering and execution, and we are excited about the potential of its ...

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling ...

NORTH CHICAGO, IL, USA I October 17, 2024 I AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ ...

Following successful Phase 1b completion, Clarametyx is initiating the Phase 2a portion to assess CMTX-101 as an adjunct to standard of care for chronic ...

SAN FRANCISCO, CA, USA and SUZHOU, China I October 16, 2024 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...

PARIS, France I October 17, 2024 I Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to ...

PRINCETON, NJ, USA I October 15, 2024 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...

BETHESDA, MD & GAITHERSBURG, MD, USA I October 16 2024 I Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools ...

Transition into clinical-stage development marks a significant corporate and R&D milestone.